Alamar Biosciences (ALMR) 10% Owner Ltd. Sells $4.8M of Stock

By TradeTexts Research Desk Oct 19, 2026, 5:02 PM EDT

Alamar Biosciences, Inc. (ALMR) business photo

Key Points

Qiming Corporate GP VI, Ltd. sold 173,537 shares of Alamar Biosciences, Inc. at $27.73 per share on October 15, 2026, lowering its holdings by 8.41% to 1,890,842 shares.
The transaction was revealed in a Form 4 filing with the Securities and Exchange Commission, showing a total sale value of about $4.8 million.
Institutional peers like Sands Capital Alternatives and Samsara BioCapital held large positions earlier in the year, while analysts from Stifel and JP Morgan maintain positive ratings.

Since the trade, $ALMR is down 4.1% to date (from the $27.42 close on Oct 15, 2026).

Get Alamar Biosciences text alerts

We text you when insiders, Congress, analysts or big funds move on $ALMR.

By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Alamar Biosciences, Inc. alert may contain errors. Disclosures

Inside Qiming Corporate GP VI's Alamar Biosciences Trade

Qiming Corporate GP VI, Ltd., a 10% owner of Alamar Biosciences, Inc. (ALMR), sold 173,537 shares of the company on October 15, 2026. The transaction was revealed in a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $27.73 each, bringing the total value of the sale to approximately $4.81 million. Following this transaction, the entity retains 1,890,842 shares, which marks an 8.41% decrease in its holdings.

ALMR Alamar Biosciences, Inc.

$26.30 +1.35% past 3 months

Daily close · Oct 19, 2026

Other Institutional Activity in Alamar Biosciences

Other major institutional investors adjusted their positions earlier in the year. Sands Capital Alternatives, LLC grew its holdings by 2,115,463 shares, ending with 4,230,926 shares worth about $111.27 million. Samsara BioCapital, LLC grew its holdings by 1,240,155 shares, ending with 2,480,310 shares worth about $65.23 million. ARK Investment Management, LLC grew its holdings by 686,980 shares, ending with 1,373,959 shares worth about $36.14 million. Braidwell LP grew its holdings by 541,992 shares, ending with 1,083,983 shares worth about $28.51 million. Alliancebernstein L.P. grew its holdings by 501,538 shares, ending with 1,003,077 shares worth about $26.38 million.

Alamar Biosciences Stock Snapshot

Alamar Biosciences shares recently traded around $26.30 as of October 19, 2026. Insider trades and institutional shifts continue to draw market attention as investors track large shareholders and their portfolio adjustments.

Insider Buying and Selling at Alamar Biosciences, Inc.

Prior to this sale, other insiders executed trades earlier in the year. On April 20, 2026, Director Nicholas J. Naclerio bought 235,294 shares at a price of $22.00, for a total value of about $5.18 million. On the same date, beneficial owner L.L.C. Illumina Innovation Fund II Gp bought 235,294 shares at a price of $22.00, totaling about $5.18 million.

Analysts Set New Price Targets

Wall Street analysts have updated their outlooks on the company. On August 11, 2026, Stifel maintained its Buy rating on the stock while raising its price target from $28.00 to $32.00. On the same day, JP Morgan maintained its Overweight rating and raised its price target from $32.00 to $35.00.

About Alamar Biosciences

Alamar Biosciences, Inc. operates in the life sciences sector, developing advanced proteomics technology platforms designed to help researchers detect disease biomarkers with high sensitivity. Precision tools of this nature support early diagnostics and drug discovery efforts across the biotech industry.

Bottom Line

Investors will continue watching Form 4 filings for further ownership updates from Qiming Corporate GP VI, Ltd. and other major stakeholders. Market participants also look ahead to upcoming analyst coverage updates and broader sector trends.